Acurx Pharmaceuticals, Inc.
STATEN ISLAND, NY · Founded 2017 · CIK 0001736243 · Biotech · Private
Novel antibiotics targeting priority pathogenic bacteria, currently in Phase 2b development for C. difficile infection treatment
acurxpharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $17M
- 7 Form D · Apr 2026
- 5 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 11
- 2 granted · 9 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,081,500 | |
| Private capital raised | Form D · SEC | $455,000 | |
| Private capital raised | Form D · SEC | $2,404,259 | |
| Private capital raised | Form D · SEC | $3,376,350 | |
| Private capital raised | Form D · SEC | $12,000,000 | |
| Private capital raised | Form D · SEC | $3,978,664 | |
| Private capital raised | Form D · SEC | $4,587,473 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2301 | Basking Biosciences | — | $29M |
| 2302 | GALATEA BIO INC | — | $3.7M |
| 2303 | Relay Therapeutics | — | $30M |
| 2304 | Acurx Pharmaceuticals, Inc. | — | $17M |
| 2305 | Congruence Therapeutics | — | — |
| 2306 | BICYCLE THERAPEUTICS PLC | — | $555M |
| 2307 | Gatehouse Bio, Inc. | — | $5.4M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Paul BaehrDirector
- Jack DeanDirector
- JACK DEANDirector
- Robert DeLucciaDirector · Executive Officer
- ROBERT DELUCCIADirector · Executive Officer
- James DonohueDirector
- JAMES DONOHUEDirector
- Michael DuffyDirector
- Thomas HarrisonDirector
- THOMAS HARRISONDirector
- Anthony JadhonDirector
- Katie JadhonDirector
- David LuciDirector · Executive Officer
- DAVID LUCIDirector · Executive Officer
- Mark RathjenDirector
- Carl SailerDirector
- CARL SAILERDirector
- Joseph ScodariDirector
- JOSEPH SCODARIDirector
- Robert ShawahExecutive Officer
- ROBERT SHAWAHExecutive Officer
- John TerranaDirector
Patents
- Compounds and Methods for Improving Healthapplication
- DNA Polymerase IIIC Inhibitors and Use Thereofgranted
- Use of Ibezapolstat to Promote Microbiome Healthapplication
- Use of Ibezapolstat to Promote Microbiome Healthgranted
- Compounds and Methods for Improving Microbiome Healthapplication
- Compounds And Methods For Improving Microbiome Healthapplication
- Compounds and Methods for Improving Microbiome Healthapplication
- Compounds And Methods For Improving Healthapplication
- Inhibitors of DNA Polymerase IIIC in Gram-Positive Bacteria, Pharmaceutical Compositions Thereof, and Uses Thereofapplication
- Inhibitors of DNA Polymerase IIIC in Gram-Positive Bacteria, Pharmaceutical Compositions Thereof, and Uses Thereofapplication
- Inhibitors Of Dna Polymerase Iiic In Gram-positive Bacteria, Pharmaceutical Compositions Thereof, And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.